Results of enforced expression of AKR1C3 in ALL-11 xenografted mice and treatment with PR-104 at 200 mg/kg for 2 weeks
| . | Treatment . | EFS, d . | LGD, d . | P value PR-104 vs vehicle . | Median ORM . | Overall response . |
|---|---|---|---|---|---|---|
| Untransduced | Vehicle | 10.1 | ||||
| ALL-11 | PR-104 | 27.2 | 17.1 | .014 | 6 | PR |
| Empty vector | Vehicle | 12.9 | ||||
| control | PR-104 | 31.3 | 18.4 | <.0001 | 6 | PR |
| AKR1C3 | Vehicle | 12.8 | ||||
| cDNA | PR-104 | 55.8 | 43.0 | <.0001 | 9 | CR |
| . | Treatment . | EFS, d . | LGD, d . | P value PR-104 vs vehicle . | Median ORM . | Overall response . |
|---|---|---|---|---|---|---|
| Untransduced | Vehicle | 10.1 | ||||
| ALL-11 | PR-104 | 27.2 | 17.1 | .014 | 6 | PR |
| Empty vector | Vehicle | 12.9 | ||||
| control | PR-104 | 31.3 | 18.4 | <.0001 | 6 | PR |
| AKR1C3 | Vehicle | 12.8 | ||||
| cDNA | PR-104 | 55.8 | 43.0 | <.0001 | 9 | CR |
CR, complete response; EFS, event-free survival; LGD, leukemia growth delay; PR, partial response.